Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Rx Importation Should Be Implemented At State Level, Attorneys General Say

  • News

Executive Summary

A state-based drug reimportation system is being recommended by state attorneys general

You may also be interested in...



CVS Endorses Imports; Infrastructure Already In Place, CEO Says

Much of the infrastructure for importing drugs is already in place, CVS CEO Thomas Ryan said May 5 at a meeting of the HHS importation task force

CVS Endorses Imports; Infrastructure Already In Place, CEO Says

Much of the infrastructure for importing drugs is already in place, CVS CEO Thomas Ryan said May 5 at a meeting of the HHS importation task force

Import Debate Crosses Border: Canada Begins To Act On Supply Issues

Health Canada is conducting inspections of Canadian pharmacies that are thought to be acting as wholesalers for the purpose of exporting drugs to the U.S

Table

View full table

Related Content

Pink Sheet
Tags:
Latest Headlines

Simplified Clinical Trial Transparency Rules To Go Live In The EU In June

Changes To EU Pharma Reform: More Questions Than Answers?

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

See All
UsernamePublicRestriction

Register

PS043948

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By